Regenerx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announced that researchers have correlated Tβ4 levels with the clinical course of profession with hepatitis B virus-related liver failure. It was reported that serum thymosin β4 levels were significantly lower in profession with chronic hepatitis B septicity and that the mass of the reduction of thymosin β4 was closely related to the severity of the hepatic injury and to patient death. Since profession with higher Tβ4 levels survived the disease, changes in Tβ4 values could reflect outcome in some liver failure patients...

More: - From the site